CoChat

Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products

Open access
Fialkow, Jonathan · 2016 · American Journal of Cardiovascular Drugs

The DOI matches its Crossref record; 87 of the 89 references it cites were found in a registry or an index.

Abstract

Omega-3 fatty acid products are available as prescription formulations (icosapent ethyl, omega-3-acid ethyl esters, omega-3-acid ethyl esters A, omega-3-carboxylic acids) and dietary supplements (predominantly fish oils). Most dietary supplements and all but one prescription formulation contain mixtures of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Products containing both EPA and DHA may raise low-density lipoprotein cholesterol (LDL-C). In clinical trials, the EPA-only prescription product, icosapent ethyl, did not raise LDL-C compared with placebo. To correct a common misconception, it is important to note that omega-3 fatty acid dietary supplements are not US FDA-approved over-the-counter drugs and are not required to demonstrate safety and efficacy prior to marketing. Conversely, prescription products are supported by extensive clinical safety and efficacy investigations required for FDA approval and have active and ongoing safety monitoring programs. While omega-3 fatty acid dietary supplements may have a place in the supplementation of diet, they generally contain lower levels of EPA and DHA than prescription products and are not approved or intended to treat disease. Perhaps due to the lack of regulation of dietary supplements, EPA and DHA levels may vary widely within and between brands, and products may also contain unwanted cholesterol or fats or potentially harmful components, including toxins and oxidized fatty acids. Accordingly, omega-3 fatty acid dietary supplements should not be substituted for prescription products. Similarly, prescription products containing DHA and EPA should not be substituted for the EPA-only prescription product, as DHA may raise LDL-C and thereby complicate the management of patients with dyslipidemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40256-016-0170-7

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Structures of omega-3 fatty acids. Both omega-6 and omega-3 fatty acids are polyunsaturated fatty acids, meaning that the hydrocarbon chain contains multiple double bonds. The naming convention is [number of carbon atoms]:[number of double bonds], n- (or ω)-[position of first double bond starting from the methyl end of the chain, shown in red]. Omega-3 fatty acids generally have anti-inflammatory and anti-thrombotic properties, whereas omega-6 fatty acids generally have pro-inflammatory and pro-thrombotic properties
Fig. 1 Structures of omega-3 fatty acids. Both omega-6 and omega-3 fatty acids are polyunsaturated fatty acids, meaning that the hydrocarbon chain contains multiple double bonds. The naming convention is [number of carbon atoms]:[number of double bonds], n- (or ω)-[position of first double bond starting from the methyl end of the chain, shown in red]. Omega-3 fatty acids generally have anti-inflammatory and anti-thrombotic properties, whereas omega-6 fatty acids generally have pro-inflammatory and pro-thrombotic propertiesCC BY-NC · PubMed Central
Fig. 2 Omega-3 fatty acids are components of triglycerides and phospholipids, and may also be found as free fatty acids. Star indicates sn-2 position; phospholipase A2 releases fatty acids from the sn-2 position of membrane phospholipids
Fig. 2 Omega-3 fatty acids are components of triglycerides and phospholipids, and may also be found as free fatty acids. Star indicates sn-2 position; phospholipase A2 releases fatty acids from the sn-2 position of membrane phospholipidsCC BY-NC · PubMed Central
Fig. 3 Percentage change from baseline versus placebo in key lipid parameters from clinical trials of prescription omega-3 fatty acid products (4 g/day) in patients with very high triglycerides (≥500 mg/dl) [48–50, 54]. Upper limit for triglycerides was 2000 mg/dl in studies of omega-3-acid ethyl esters, omega-3-carboxylic acids, and icosapent ethyl and 1500 mg in the omega-3-acid ethyl esters A study. Omega-3-acid ethyl esters values are based on pooled data from two studies [10, 11] (6 and 16 weeks’ duration) as reported in the omega-3-acid ethyl esters prescribing information [48]. Icosapent ethyl data are from the MARINE (Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study with an Open-Label Extension) study (12 weeks) [12]. Omega-3-acid ethyl esters A data (12 weeks) have only been published in the product’s prescribing information [49]. Omega-3-carboxylic acids data are from the EVOLVE (Epanova for Lowering Very High Triglycerides) study (12 weeks) [13]. Difference versus placebo: omega-3-acid ethyl esters = omega-3-acid ethyl esters median % change—placebo median % change; icosapent ethyl = median of [icosapent ethyl % change—placebo % change] (Hodges–Lehmann estimate); omega-3-acid ethyl esters A = Hodges–Lehmann median of all pairwise differences from placebo; omega-3-carboxylic acids = median of [omega-3-carboxylic acids % change—placebo % change] (Hodges–Lehmann estimate). HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TC total cholesterol, TG triglycerides
Fig. 3 Percentage change from baseline versus placebo in key lipid parameters from clinical trials of prescription omega-3 fatty acid products (4 g/day) in patients with very high triglycerides (≥500 mg/dl) [48–50, 54]. Upper limit for triglycerides was 2000 mg/dl in studies of omega-3-acid ethyl esters, omega-3-carboxylic acids, and icosapent ethyl and 1500 mg in the omega-3-acid ethyl esters A study. Omega-3-acid ethyl esters values are based on pooled data from two studies [10, 11] (6 and 16 weeks’ duration) as reported in the omega-3-acid ethyl esters prescribing information [48]. Icosapent ethyl data are from the MARINE (Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study with an Open-Label Extension) study (12 weeks) [12]. Omega-3-acid ethyl esters A data (12 weeks) have only been published in the product’s prescribing information [49]. Omega-3-carboxylic acids data are from the EVOLVE (Epanova for Lowering Very High Triglycerides) study (12 weeks) [13]. Difference versus placebo: omega-3-acid ethyl esters = omega-3-acid ethyl esters median % change—placebo median % change; icosapent ethyl = median of [icosapent ethyl % change—placebo % change] (Hodges–Lehmann estimate); omega-3-acid ethyl esters A = Hodges–Lehmann median of all pairwise differences from placebo; omega-3-carboxylic acids = median of [omega-3-carboxylic acids % change—placebo % change] (Hodges–Lehmann estimate). HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TC total cholesterol, TG triglyceridesCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 4

  1. Niki T Wakatsuki T Bando M Effects of additional eicosapentaenoic acid to statin therapy on inflammatory cytokines and the tissue characterization of coronary plaque assessed by integrated backscatter intravascular ultrasound systems [abstract 14434] Circulation. 2012 126 21 Suppl. 14434
  2. Katoh A Ikeda H Daily intake of eicosapentaenoic acid inhibits the progression of carotid intimal-media thickness in patients with dyslipidemia [in Japanese] Ther Res. 2011 32 6 863 868
  3. Truong P Johnson C Gabriel D Variability of cholesterol and saturated fat content in dietary supplements [abstract P72] Circulation. 2007 115 8 e238
  4. Lopez JAG Ito MK PLA chapter update: prescription fish oil and Blue Cross of Idaho LipidSpin. 2010 8 3 32 34

Cited by

See all 83

Metadata

Authors
Fialkow, J.
Affiliations
Baptist Hospital of Miami (US)
Corresponding author
Fialkow, Jonathan
Venue
American Journal of Cardiovascular Drugs
Published
2016-04-30
Volume
16
Issue
4
Pages
229-239
ISSN
  • 1175-3277 (ISSN-L)
  • 1179-187X
OpenAlex
W2345135102
Cited by
80
References
89
Citations by year
2026: 7 · 2025: 4 · 2024: 5 · 2023: 20 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 9 · 2018: 6 · 2017: 6 · 2016: 1
FWCI
0.98
Type
journal article
Language
en
Open access
Locations
  • American Journal of Cardiovascular Drugs (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Scholarly Commons - Baptist Health South Florida (Baptist Health South Florida) (submittedVersion)
Funders
  • Amarin Corporation
  • Amarin Pharma
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
Keywords
omega-3 fatty acids, icosapent ethyl, omega-3 acid ethyl esters, dietary supplements, fish oil, eicosapentaenoic acid, docosahexaenoic acid, LDL cholesterol, dyslipidemia, cardiovascular disease, FDA regulation of dietary supplements, oxidized fatty acids
MeSH terms
Animals, Hypolipidemic Agents, Cardiovascular Diseases, Chemistry, Pharmaceutical, Diet, Docosahexaenoic Acids, Humans, Cholesterol, LDL, Eicosapentaenoic Acid, Hypertriglyceridemia, Fatty Acids, Omega-3, Dietary Supplements, Dyslipidemias, Prescription Drugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.